Royal Bank of Canada
LTRN icon

Royal Bank of Canada’s Lantern Pharma LTRN Stock Holding History

Royal Bank of Canada’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,420
Closed -$7K – 7175
2024
Q2 		$7K Buy
1,420
+1,412
+17,650% +$8.49K ﹤0.01% 6452
2024
Q1 		$0 Sell
8
-78
-91% -$417 ﹤0.01% 7336
2023
Q4 		$0 Sell
86
-20
-19% -$71 ﹤0.01% 7378
2023
Q3 		$0 Sell
106
-100
-49% -$454 ﹤0.01% 7352
2023
Q2 		$1K Buy
+206
New +$1.06K ﹤0.01% 7033
2022
Q4 		– Sell
-87
Closed – – 7508
2022
Q3 		$0 Sell
87
-45
-34% -$242 ﹤0.01% 7668
2022
Q2 		$1K Sell
132
-1,158
-90% -$6.91K ﹤0.01% 7151
2022
Q1 		$9K Buy
1,290
+1,266
+5,275% +$8.45K ﹤0.01% 6997
2021
Q4 		$0 Buy
+24
New +$219 ﹤0.01% 7801
2021
Q3 		– Sell
-13
Closed – – 7757
2021
Q2 		$0 Hold
13
– – ﹤0.01% 7595
2021
Q1 		$0 Sell
13
-987
-99% -$17.3K ﹤0.01% 7573
2020
Q4 		$19K Hold
1,000
– – ﹤0.01% 6088
2020
Q3 		$19K Buy
+1,000
New +$14.5K ﹤0.01% 5719

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Royal Bank of Canada's LTRN Position: Q3 2024 in Review

Royal Bank of Canada sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 1,420 shares — an estimated $7K sold.

Royal Bank of Canada first reported a position in LTRN in Q3 2020 and held it in 13 quarters. The position peaked at $19K in Q4 2020. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • Royal Bank of Canada reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 1,420 Lantern Pharma shares in Q3 2024, an estimated $7K.
  • Royal Bank of Canada first reported a position in Lantern Pharma in Q3 2020 and held it in 13 quarters.
  • Royal Bank of Canada's Lantern Pharma position peaked at $19K in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.